Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0090
-0.0007 (-7.22%)
Aug 22, 2025, 4:00 PM EDT
Evofem Biosciences Revenue
Evofem Biosciences had revenue of $4.83M in the quarter ending June 30, 2025, with 15.99% growth. This brings the company's revenue in the last twelve months to $17.27M, down -2.51% year-over-year. In the year 2024, Evofem Biosciences had annual revenue of $19.36M with 6.28% growth.
Revenue (ttm)
17.27M
Revenue Growth
-2.51%
P/S Ratio
0.06
Revenue / Employee
539.69K
Employees
32
Market Cap
1.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.36M | 1.15M | 6.28% |
Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
Dec 31, 2020 | 446.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Evofem Biosciences News
- 2 days ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire
- 4 days ago - FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis - PRNewsWire
- 9 days ago - Evofem Biosciences GAAP EPS of -$0.02, revenue of $4.8M - Seeking Alpha
- 9 days ago - Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update - PRNewsWire
- 18 days ago - Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - PRNewsWire
- 2 months ago - Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store - PRNewsWire
- 2 months ago - Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
- 3 months ago - Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1 - PRNewsWire